{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Virus Junin : Questions médicales les plus fréquentes",
"headline": "Virus Junin : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Virus Junin : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-21",
"dateModified": "2025-04-15",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Virus Junin"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Arénavirus du Nouveau Monde",
"url": "https://questionsmedicales.fr/mesh/D006477",
"about": {
"@type": "MedicalCondition",
"name": "Arénavirus du Nouveau Monde",
"code": {
"@type": "MedicalCode",
"code": "D006477",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.820.480.500.070.095"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Virus Junin",
"alternateName": "Junin virus",
"code": {
"@type": "MedicalCode",
"code": "D018051",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Cheng Huang",
"url": "https://questionsmedicales.fr/author/Cheng%20Huang",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America."
}
},
{
"@type": "Person",
"name": "Slobodan Paessler",
"url": "https://questionsmedicales.fr/author/Slobodan%20Paessler",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America."
}
},
{
"@type": "Person",
"name": "Duncan R Smith",
"url": "https://questionsmedicales.fr/author/Duncan%20R%20Smith",
"affiliation": {
"@type": "Organization",
"name": "Institute of Molecular Biosciences, Mahidol University, Salaya, 73170, Thailand. duncan_r_smith@hotmail.com."
}
},
{
"@type": "Person",
"name": "Vahid Rajabali Zadeh",
"url": "https://questionsmedicales.fr/author/Vahid%20Rajabali%20Zadeh",
"affiliation": {
"@type": "Organization",
"name": "Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan."
}
},
{
"@type": "Person",
"name": "Shuzo Urata",
"url": "https://questionsmedicales.fr/author/Shuzo%20Urata",
"affiliation": {
"@type": "Organization",
"name": "Department of Emerging Infectious Diseases, National Research Center for the Control and Prevention of Infectious Diseases (CCPID), Nagasaki University, Nagasaki, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Low expression of ZSCAN4 predicts unfavorable outcome in urothelial carcinoma of upper urinary tract and urinary bladder.",
"datePublished": "2023-02-25",
"url": "https://questionsmedicales.fr/article/36841776",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12957-023-02948-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "EphA2 on urinary extracellular vesicles as a novel biomarker for bladder cancer diagnosis and its effect on the invasiveness of bladder cancer.",
"datePublished": "2022-07-06",
"url": "https://questionsmedicales.fr/article/35794239",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41416-022-01860-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Thulium laser enucleation of bladder tumour (Thulebt): Changing paradigm in the management of nonmuscle invasive urinary bladder carcinoma.",
"datePublished": "2023-02-09",
"url": "https://questionsmedicales.fr/article/36756892",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/03915603231153709"
}
},
{
"@type": "ScholarlyArticle",
"name": "Diagnostic Potential of Circulating Tumor Cells, Urinary MicroRNA, and Urinary Cell-Free DNA for Bladder Cancer: A Review.",
"datePublished": "2022-08-15",
"url": "https://questionsmedicales.fr/article/36012417",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms23169148"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Development of a squamous cell carcinoma of the urinary bladder after intravesical condylomas].",
"datePublished": "2022-06-07",
"url": "https://questionsmedicales.fr/article/31940665",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/a-0761-2593"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Virus",
"item": "https://questionsmedicales.fr/mesh/D014780"
},
{
"@type": "ListItem",
"position": 3,
"name": "Virus à ARN",
"item": "https://questionsmedicales.fr/mesh/D012328"
},
{
"@type": "ListItem",
"position": 4,
"name": "Virus à ARN de polarité négative",
"item": "https://questionsmedicales.fr/mesh/D000086103"
},
{
"@type": "ListItem",
"position": 5,
"name": "Arenaviridae",
"item": "https://questionsmedicales.fr/mesh/D001116"
},
{
"@type": "ListItem",
"position": 6,
"name": "Arenavirus",
"item": "https://questionsmedicales.fr/mesh/D018050"
},
{
"@type": "ListItem",
"position": 7,
"name": "Arénavirus du Nouveau Monde",
"item": "https://questionsmedicales.fr/mesh/D006477"
},
{
"@type": "ListItem",
"position": 8,
"name": "Virus Junin",
"item": "https://questionsmedicales.fr/mesh/D018051"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Virus Junin - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Virus Junin",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Virus Junin",
"description": "Comment diagnostique-t-on l'infection par le virus Junin ?\nQuels tests sont utilisés pour confirmer le virus Junin ?\nLes symptômes aident-ils au diagnostic du virus Junin ?\nPeut-on diagnostiquer le virus Junin par culture virale ?\nLe diagnostic précoce est-il important pour le virus Junin ?",
"url": "https://questionsmedicales.fr/mesh/D018051?mesh_terms=Urinary+Bladder+Neoplasms&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Virus Junin",
"description": "Quels sont les symptômes de l'infection par le virus Junin ?\nLa fièvre est-elle un symptôme courant du virus Junin ?\nLes symptômes du virus Junin peuvent-ils varier ?\nY a-t-il des symptômes neurologiques associés au virus Junin ?\nLes symptômes apparaissent-ils rapidement après l'infection ?",
"url": "https://questionsmedicales.fr/mesh/D018051?mesh_terms=Urinary+Bladder+Neoplasms&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Virus Junin",
"description": "Comment prévenir l'infection par le virus Junin ?\nLa vaccination contre le virus Junin est-elle disponible ?\nQuelles mesures d'hygiène sont recommandées ?\nLes rongeurs sont-ils un vecteur de transmission ?\nLes voyageurs doivent-ils se vacciner contre le virus Junin ?",
"url": "https://questionsmedicales.fr/mesh/D018051?mesh_terms=Urinary+Bladder+Neoplasms&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Virus Junin",
"description": "Quel est le traitement principal pour l'infection par le virus Junin ?\nDes antiviraux sont-ils efficaces contre le virus Junin ?\nLa transfusion sanguine est-elle utilisée dans le traitement ?\nLe traitement précoce améliore-t-il le pronostic ?\nY a-t-il des traitements expérimentaux pour le virus Junin ?",
"url": "https://questionsmedicales.fr/mesh/D018051?mesh_terms=Urinary+Bladder+Neoplasms&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Virus Junin",
"description": "Quelles sont les complications possibles de l'infection par le virus Junin ?\nLes complications surviennent-elles souvent ?\nLe virus Junin peut-il causer des séquelles à long terme ?\nLes complications sont-elles plus fréquentes chez certains groupes ?\nComment gérer les complications du virus Junin ?",
"url": "https://questionsmedicales.fr/mesh/D018051?mesh_terms=Urinary+Bladder+Neoplasms&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Virus Junin",
"description": "Quels sont les principaux facteurs de risque pour le virus Junin ?\nLes agriculteurs sont-ils à risque d'infection par le virus Junin ?\nLes personnes immunodéprimées sont-elles plus vulnérables ?\nLe sexe influence-t-il le risque d'infection par le virus Junin ?\nLes personnes vivant en milieu urbain sont-elles à risque ?",
"url": "https://questionsmedicales.fr/mesh/D018051?mesh_terms=Urinary+Bladder+Neoplasms&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on l'infection par le virus Junin ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sérologiques et PCR pour détecter le virus."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer le virus Junin ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests ELISA et la PCR sont couramment utilisés pour confirmer l'infection."
}
},
{
"@type": "Question",
"name": "Les symptômes aident-ils au diagnostic du virus Junin ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes cliniques orientent le diagnostic, mais des tests sont nécessaires."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer le virus Junin par culture virale ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La culture virale est possible mais moins courante en raison des risques de contagion."
}
},
{
"@type": "Question",
"name": "Le diagnostic précoce est-il important pour le virus Junin ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un diagnostic précoce permet une prise en charge rapide et améliore le pronostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de l'infection par le virus Junin ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fièvre, myalgies, fatigue, et parfois des hémorragies."
}
},
{
"@type": "Question",
"name": "La fièvre est-elle un symptôme courant du virus Junin ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fièvre est l'un des symptômes les plus fréquents de l'infection."
}
},
{
"@type": "Question",
"name": "Les symptômes du virus Junin peuvent-ils varier ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la nature des symptômes peuvent varier d'une personne à l'autre."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés au virus Junin ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes neurologiques peuvent survenir, notamment des troubles de la conscience."
}
},
{
"@type": "Question",
"name": "Les symptômes apparaissent-ils rapidement après l'infection ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes apparaissent généralement 1 à 3 semaines après l'exposition au virus."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'infection par le virus Junin ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par l'évitement des contacts avec les rongeurs et la vaccination."
}
},
{
"@type": "Question",
"name": "La vaccination contre le virus Junin est-elle disponible ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une vaccination est disponible et recommandée pour les populations à risque."
}
},
{
"@type": "Question",
"name": "Quelles mesures d'hygiène sont recommandées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des mesures d'hygiène strictes, comme le nettoyage des lieux infestés, sont essentielles."
}
},
{
"@type": "Question",
"name": "Les rongeurs sont-ils un vecteur de transmission ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les rongeurs sont les principaux réservoirs et vecteurs du virus Junin."
}
},
{
"@type": "Question",
"name": "Les voyageurs doivent-ils se vacciner contre le virus Junin ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les voyageurs se rendant dans des zones endémiques doivent envisager la vaccination."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal pour l'infection par le virus Junin ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement est principalement symptomatique, avec des soins de soutien en cas de gravité."
}
},
{
"@type": "Question",
"name": "Des antiviraux sont-ils efficaces contre le virus Junin ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas d'antiviraux spécifiques approuvés pour le virus Junin."
}
},
{
"@type": "Question",
"name": "La transfusion sanguine est-elle utilisée dans le traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des transfusions peuvent être nécessaires en cas de complications hémorragiques sévères."
}
},
{
"@type": "Question",
"name": "Le traitement précoce améliore-t-il le pronostic ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un traitement précoce et approprié peut améliorer le pronostic des patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux pour le virus Junin ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur des traitements expérimentaux, mais rien n'est encore validé."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de l'infection par le virus Junin ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent inclure des hémorragies, des troubles neurologiques et la mort."
}
},
{
"@type": "Question",
"name": "Les complications surviennent-elles souvent ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications graves sont rares mais peuvent survenir chez certains patients."
}
},
{
"@type": "Question",
"name": "Le virus Junin peut-il causer des séquelles à long terme ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des séquelles neurologiques peuvent persister après la guérison de l'infection."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles plus fréquentes chez certains groupes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes immunodéprimées sont plus à risque de complications sévères."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications du virus Junin ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite des soins médicaux intensifs et un suivi approprié."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour le virus Junin ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'exposition aux rongeurs et le travail en zones endémiques."
}
},
{
"@type": "Question",
"name": "Les agriculteurs sont-ils à risque d'infection par le virus Junin ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les agriculteurs travaillant dans des zones infestées par des rongeurs sont à risque."
}
},
{
"@type": "Question",
"name": "Les personnes immunodéprimées sont-elles plus vulnérables ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles présentent un risque accru de développer des formes graves de la maladie."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque d'infection par le virus Junin ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent que le risque peut varier selon le sexe, mais les raisons ne sont pas claires."
}
},
{
"@type": "Question",
"name": "Les personnes vivant en milieu urbain sont-elles à risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le risque est généralement plus faible en milieu urbain, mais des cas sporadiques peuvent survenir."
}
}
]
}
]
}
With the advance in genome-wide analyses, genetic alternations have been found to play an important role in carcinogenesis and aggressiveness of UC. Through bioinformatic analysis of gene expression p...
The expression of ZSCAN4 was evaluated by immunohistochemistry in 340 upper urinary tract urothelial carcinomas (UTUCs) and 295 UBUCs. The expression profiles of ZSCAN4 and potential signaling pathway...
In UTUC, low expression of ZSCAN4 was significantly associated with advanced primary pT stage (P = 0.011), increased nodal metastasis (P = 0.002) and increased vascular invasion (P = 0.019). In UBUC, ...
Low expression of ZSCAN4 predicted worse outcome in urothelial carcinoma and might have potential regulatory role in cell mitosis....
Urinary extracellular vesicles (uEVs) secreted from bladder cancer contain cancer-specific proteins that are potential diagnostic biomarkers. We identified and evaluated a uEV-based protein biomarker ...
Biomarker candidates, selected by shotgun proteomics, were validated using targeted proteomics of uEVs obtained from 49 patients with and 48 individuals without bladder cancer, including patients with...
Thirteen membrane proteins were significantly upregulated in the uEVs from patients with bladder cancer in shotgun proteomics. Among them, eight proteins were validated by target proteomics, and Ephri...
We established EV-EphA2-CD9 ELISA for uEV-EphA2 detection for the non-invasive early clinical diagnosis of bladder cancer....
To analyse the safety and efficacy of Thulium laser en bloc enucleation of bladder tumour (ThuLEBT) in comparison to transurethral resection of bladder tumour (TURBT) for treatment of non-muscle invasiv...
Prospective observational study involving 30 patients in each group of ThuLEBT and TURBT admitted in tertiary care centre from 1st January 2021 to December 2021....
Significant difference was found in terms of less operative time (...
ThuLEBT is an efficient and safe treatment for non-muscle invasive bladder cancer and it can be a better alternative choice in place of TURBT....
Early detection of primary bladder cancer (BCa) is vital, because stage and grade have been generally accepted not only as categorical but also as prognostic factors in patients with BCa. The widely a...
The occurrence of intravesical condylomata acuminata has been described as a fairly uncommon, benign epithelial lesion. Reports on progression into a muscle-invasive carcinoma of the bladder are rare....
We present the case of a 68-year-old man who had a history of intravesical condylomata acuminata over several years and developed a muscle-invasive squamous cell carcinoma of the bladder. Having under...
The carcinogenic potency of the human papilloma virus is well known for carcinomas of the male and female genitals. The occurrence of intravesical condylomata is rare. They are commonly perceived as b...
The diagnosis of intravesical condylomata acuminata requires stringent urologic follow-up examinations including biopsy of suspicious lesions and stage-appropriate surgical management in the case of a...
We sought to investigate the change in the urinary microbiome profile after transurethral resection of bladder tumor (TURBT)....
Urine specimens were collected from consecutive patients with bladder cancer. Patients were divided into those with bladder tumors ("Tumor group": de novo tumors or recurrent/progressed after TURBT ± ...
Sixty-eight samples were analyzed (42 in "Tumor" vs 26 in "No Recurrent Tumor" groups). The median age was 70 years (IQR 64-74) and 85% were males. All patients in the "No Recurrent Tumor" group had n...
Bladder cancer patients with no recurrence and/or progression exhibited a different urinary microbiome profile compared to those with tumors....
To detect the expression level of urinary exosomal lncRNA SNHG16 in patients with bladder cancer and healthy individuals and explore its clinical application value in the diagnosis of bladder cancer....
Urine samples were collected from 42 patients with bladder cancer and 42 healthy volunteers who visited Lu'an Hospital of Anhui Medical University and the Second Hospital of Tianjin Medical University...
The expression of urinary exosomal lncRNA SNHG16 in patients with bladder cancer was significantly higher (P < 0.05), and the expression level had no correlation with the age, sex, pathological T stag...
Urinary exosomal lncRNA SNHG16 with high expression can serve as a potential diagnostic biological marker for bladder cancer....
Particulate matter and volatile organic compounds, including total hydrocarbons (THCs), are major ambient air pollutants. Primary nonmethane hydrocarbons (NMHCs) originate from vehicle emissions. The ...
Recent interest in noninvasive diagnostic approaches has highlighted the potential of urinary microbiota as a novel biomarker for bladder cancer. This study investigated the urinary microbiota of 30 b...
Bladder cancer (BC) is among the most common cancers diagnosed in men in the USA. The current gold standards for the diagnosis of BC are invasive or lack the sensitivity to correctly identify the dise...
An aptamer-based screen analyzed the expression of 1317 proteins in BC compared to urology clinic controls. The top hits were subjected to systems biology analyses. Next, 30 urine proteins were ELISA-...
Systems biology analysis implicated molecular functions related to the extracellular matrix, collagen, integrin, heparin, and transmembrane tyrosine kinase signaling in BC susceptibility, with HNF4A a...
Given the high sensitivity (97%) of urine D-dimer for BC, it may have a role in the initial diagnosis or detection of cancer recurrence. On the other hand, urine IL-8 and IgA may have the potential in...